# Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms

> **NCT04629885** · PHASE2 · COMPLETED · sponsor: **PepTonic Medical AB** · enrollment: 202 (actual)

## Conditions studied

- Vulvovaginal Atrophy

## Interventions

- **DRUG:** Oxytocin 400 IU vaginal gel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04629885
- **Lead sponsor:** PepTonic Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-03
- **Primary completion:** 2017-05-03
- **Final completion:** 2017-05-03
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2020-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629885, "Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04629885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*